Abstract:The combined effects of lung tumor motion and limitations of treatment planning system dose calculations in lung regions increases uncertainty in dose delivered to the tumor and surrounding normal tissues in lung stereotactic body radiotherapy (SBRT). This study investigated the effect on plan quality and accuracy when overriding treatment volume electron density values. The QUASAR phantom with modified cork cylindrical inserts, each containing a simulated spherical tumor of 15‐mm, 22‐mm, or 30‐mm diameter, wa… Show more
“…[20][21][22] Although an anthropomorphic phantom is nowadays the best representation of the actual patient anatomy, the sizes of the water-equivalent targets are in general still large compared to the small tumor volumes encountered in patients that eligible for SBRT. 23 For example, the phantom used by Sepp€ al€ a et al 24 contains a spherical target of 1.5 and 4.0 cm in diameter, which would clinically be treated with SBRT (maximum diameter ≤5.0 cm, RTOG 0236) but such a large volume does not pose a serious challenge to type "b" or "c" algorithms as their results showed. [25][26][27] It is therefore interesting to investigate when type "c" dose calculation algorithms start to deviate beyond a relative uncertainty of 5%, 12 especially for very small tumors with tumor diameters below 1 cm, that are nowadays treated with SBRT.…”
Section: Introductionmentioning
confidence: 99%
“…A dosimetric plan verification setup is chosen using either an inhomogeneous slab phantom or more sophisticated anthropomorphic phantoms with a spherical water‐equivalent target inside lung‐equivalent material to verify the TPS dose prediction with actual measurements 20–22 . Although an anthropomorphic phantom is nowadays the best representation of the actual patient anatomy, the sizes of the water‐equivalent targets are in general still large compared to the small tumor volumes encountered in patients that eligible for SBRT 23 . For example, the phantom used by Seppälä et al 24 contains a spherical target of 1.5 and 4.0 cm in diameter, which would clinically be treated with SBRT (maximum diameter ≤5.0 cm, RTOG 0236) but such a large volume does not pose a serious challenge to type “b” or “c” algorithms as their results showed 25–27 …”
Purpose
Modern type ‘c’ dose calculation algorithms like Acuros® can predict dose for lung tumors larger than approximately 4 cm3 with a relative uncertainty up to 5%. However, increasingly better tumor diagnostics are leading to the detection of very small early‐stage lung tumors that can be treated with stereotactic body radiotherapy (SBRT) for inoperable patients. This raises the question whether dose algorithms like Acuros® can still accurately predict dose within 5% for challenging conditions involving small treatment fields. Current recommendations for Quality Assurance (QA) and dose verification in SBRT treatments are to use phantoms that are as realistic as possible to the clinical situation, although water‐equivalent phantoms are still largely used for dose verification. In this work we aim to demonstrate that existing dose verification methods are inadequate for accurate dose verification in very small lung tumors treated with SBRT.
Method
The homogeneous PTW Octavius4D phantom with the Octavius 1000 SRS detector (“Octavius4D phantom”) and the heterogeneous CIRS Dynamic Thorax phantom (‘CIRS phantom’) were used for dose measurements. The CIRS phantom contained different lung‐equivalent film‐holding cylindrical phantom inserts (“film inserts”) with water‐equivalent spherical targets with diameters 0.5, 0.75, 1, 2, and 3 cm. Plans were calculated for 6 and 10 MV for each spherical target in the CIRS phantom, resulting in 14 treatment plans. The plans were delivered to both Octavius4D and CIRS phantom to compare measured dose in a commonly used homogeneous and more realistic heterogeneous phantom setup. In addition, treatment plans of seven clinical lung cancer patients with lung tumors below approximately 1.0 cm3 were irradiated in the heterogeneous CIRS phantom. The actual tumor size within the clinical treatment plans determined the choice of the spherical target size, such that both measurement geometry and clinical target volumes match as closely as possible. The Acuros® dose algorithm (version 15.5.11) was used for all dose calculations reporting dose‐to‐medium using a 0.1‐cm‐grid size.
Results
The measurement discrepancies in the homogeneous Octavius4D phantom for the fourteen treatment plans were within 1.5%. Dose discrepancies between measurement and treatment planning systems (TPS) for the heterogeneous CIRS phantom increased for both 6 and 10 MV with decreasing target diameters up to 23.7 ± 1.0% for 6 MV and 8.8 ± 1.1% for 10 MV for the smallest target of 0.5 cm in diameter with a 2‐mm‐CTV‐PTV margin. For the seven clinical plans this trend of increasing dose difference with decreasing tumor size is less pronounced although the smallest tumors show the largest differences between measurement and TPS up to 16.6 ± 0.9%.
Conclusion
Current verification methods using homogenous phantoms are not adequate for lung tumors with diameters below approximately 0.75 cm. The current Acuros® dose calculation algorithm underestimates dose in very small lung tumors. Dose verification of small lung tumors should...
“…[20][21][22] Although an anthropomorphic phantom is nowadays the best representation of the actual patient anatomy, the sizes of the water-equivalent targets are in general still large compared to the small tumor volumes encountered in patients that eligible for SBRT. 23 For example, the phantom used by Sepp€ al€ a et al 24 contains a spherical target of 1.5 and 4.0 cm in diameter, which would clinically be treated with SBRT (maximum diameter ≤5.0 cm, RTOG 0236) but such a large volume does not pose a serious challenge to type "b" or "c" algorithms as their results showed. [25][26][27] It is therefore interesting to investigate when type "c" dose calculation algorithms start to deviate beyond a relative uncertainty of 5%, 12 especially for very small tumors with tumor diameters below 1 cm, that are nowadays treated with SBRT.…”
Section: Introductionmentioning
confidence: 99%
“…A dosimetric plan verification setup is chosen using either an inhomogeneous slab phantom or more sophisticated anthropomorphic phantoms with a spherical water‐equivalent target inside lung‐equivalent material to verify the TPS dose prediction with actual measurements 20–22 . Although an anthropomorphic phantom is nowadays the best representation of the actual patient anatomy, the sizes of the water‐equivalent targets are in general still large compared to the small tumor volumes encountered in patients that eligible for SBRT 23 . For example, the phantom used by Seppälä et al 24 contains a spherical target of 1.5 and 4.0 cm in diameter, which would clinically be treated with SBRT (maximum diameter ≤5.0 cm, RTOG 0236) but such a large volume does not pose a serious challenge to type “b” or “c” algorithms as their results showed 25–27 …”
Purpose
Modern type ‘c’ dose calculation algorithms like Acuros® can predict dose for lung tumors larger than approximately 4 cm3 with a relative uncertainty up to 5%. However, increasingly better tumor diagnostics are leading to the detection of very small early‐stage lung tumors that can be treated with stereotactic body radiotherapy (SBRT) for inoperable patients. This raises the question whether dose algorithms like Acuros® can still accurately predict dose within 5% for challenging conditions involving small treatment fields. Current recommendations for Quality Assurance (QA) and dose verification in SBRT treatments are to use phantoms that are as realistic as possible to the clinical situation, although water‐equivalent phantoms are still largely used for dose verification. In this work we aim to demonstrate that existing dose verification methods are inadequate for accurate dose verification in very small lung tumors treated with SBRT.
Method
The homogeneous PTW Octavius4D phantom with the Octavius 1000 SRS detector (“Octavius4D phantom”) and the heterogeneous CIRS Dynamic Thorax phantom (‘CIRS phantom’) were used for dose measurements. The CIRS phantom contained different lung‐equivalent film‐holding cylindrical phantom inserts (“film inserts”) with water‐equivalent spherical targets with diameters 0.5, 0.75, 1, 2, and 3 cm. Plans were calculated for 6 and 10 MV for each spherical target in the CIRS phantom, resulting in 14 treatment plans. The plans were delivered to both Octavius4D and CIRS phantom to compare measured dose in a commonly used homogeneous and more realistic heterogeneous phantom setup. In addition, treatment plans of seven clinical lung cancer patients with lung tumors below approximately 1.0 cm3 were irradiated in the heterogeneous CIRS phantom. The actual tumor size within the clinical treatment plans determined the choice of the spherical target size, such that both measurement geometry and clinical target volumes match as closely as possible. The Acuros® dose algorithm (version 15.5.11) was used for all dose calculations reporting dose‐to‐medium using a 0.1‐cm‐grid size.
Results
The measurement discrepancies in the homogeneous Octavius4D phantom for the fourteen treatment plans were within 1.5%. Dose discrepancies between measurement and treatment planning systems (TPS) for the heterogeneous CIRS phantom increased for both 6 and 10 MV with decreasing target diameters up to 23.7 ± 1.0% for 6 MV and 8.8 ± 1.1% for 10 MV for the smallest target of 0.5 cm in diameter with a 2‐mm‐CTV‐PTV margin. For the seven clinical plans this trend of increasing dose difference with decreasing tumor size is less pronounced although the smallest tumors show the largest differences between measurement and TPS up to 16.6 ± 0.9%.
Conclusion
Current verification methods using homogenous phantoms are not adequate for lung tumors with diameters below approximately 0.75 cm. The current Acuros® dose calculation algorithm underestimates dose in very small lung tumors. Dose verification of small lung tumors should...
“…Esto puede ser conveniente en algunos casos en los que el CTV esté rodeado de grandes heterogeneidades, por ejemplo, pulmón. 203,204 • Disminuyendo el grado de modulación de intensidad cuando haya movimientos respiratorios/cardíacos o, en general, riesgo de movimientos intrafracción (ver siguiente apartado).…”
El contenido del documento refleja las recomendaciones de la SEFM para el control de calidad y uso seguro de los sistemas de planificación de radioterapia externa. Se hace una exposición inicial de los motivos, consideraciones generales y principales novedades a tener en cuenta en los sistemas de planificación actuales, para pasar a analizar detalladamente la caracterización de las unidades de tratamiento y los parámetros que hay que tener en cuenta en el modelado de las mismas, haciendo especial hincapié en aquellos que tienen que ver con el colimador multilámina. En el documento se distinguen tres secciones diferentes que tratan de abarcar todo aquello que influye en que el producto del sistema de planificación, el plan de tratamiento, tenga la mejor calidad y seguridad asociada: control de calidad del sistema de planificación, garantía de calidad del proceso de planificación y verificación de planes de tratamiento, todo ello siempre manteniendo la visión que proporciona el análisis de riesgos asociado.
El programa de control de calidad se establece en tres pasos: estado de referencia inicial, controles periódicos y controles tras actualizaciones. Añadido a esto, se analiza el proceso de planificación y cómo garantizar la calidad en el mismo por medio de procesos globales (auditorías y pruebas end-to-end), evaluación de planes y sistematización relacionada con la protocolización y las soluciones de clase. Por último, se describen las herramientas de verificación de planes y sus limitaciones, las métricas asociadas así como las estrategias de verificación posibles. Todo el documento culmina con un último capítulo que resume todas las recomendaciones basándose en lo expuesto y concreta las tolerancias a utilizar en cada etapa.
“…9 This effect can be offset by mathematical transformation, where the blurring is considered as a convolution of the static dose distributions that would result when there is no motion. 9 However, while this strategy has been applied in several studies using radiochromic films and has been proven to function well in most clinical situations, [10][11][12] it is not used clinically because it is not available in most treatment planning systems (TPSs) or QA tools. Moreover, it can introduce uncertainties that are difficult to estimate, such as when using deformable image registration maps to accumulate the dose matrix.…”
Purpose
A common dosimetric quality assurance (QA) method in stereotactic body radiation therapy (SBRT) of lung tumors is to use lung phantoms with radiochromic film. However, in most phantoms, the film moves with the tumor, leading to the blurring effect. This technical note presents the QA performance of a novel phantom in which the film is fixed; this phantom can be used for both patient‐specific QA and end‐to‐end testing.
Methods
Lung tumor motion was simulated with the CIRS Model 008A phantom. A lung‐equivalent insert that consisted of a fixed radiochromic film around which a 2‐cm tumor moved in the inferior/superior direction (i.e., mimicking respiration‐induced tumor motion) was generated by 3D printing. Two common SBRT plans [dynamic conformal arc (DCA) and volumetric‐modulated arc therapy (VMAT)] were calculated on the average intensity projection (AIP) image set in Varian Eclipse using the dose calculation algorithm Acuros XB. The plans were delivered by a Varian TrueBeam STx accelerator using 6‐MV flattening filter‐free energy. EBT3 films were used for treatment‐dose verification. The measured and planned dose distributions were compared by using the local gamma index at 3% and 2 mm.
Results
Mean gamma pass rates of film and planned dose distributions were all ≥95%. DCA and VMAT plans did not differ in gamma pass rates. Planned and measured dose distributions agreed well, as did planned and measured gamma maps.
Conclusions
With this new insert, measured and planned dose distributions were very similar, which supports the current view in the field that dose calculations on AIP image sets account sufficiently for tumor motion during treatment. The phantom also performed well despite challenging breathing parameters (large tumor amplitude and slow breathing rate) and the application of a complex treatment technique (VMAT). This phantom could facilitate clinical and end‐to‐end film‐based dosimetric QA for lung SBRT.
Taxonomy
Twenty‐seven TH‐ Radiation dose measurement devices. Eleven Phantoms for dosimetric measurement.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.